Immuron Ltd — Regulatory Filings 2017

May 8, 2017

==> picture [563 x 98] intentionally omitted <==

==> picture [562 x 101] intentionally omitted <==

----- Start of picture text ----- PRESS RELEASE: May 9, 2017----- End of picture text -----

==> picture [562 x 101] intentionally omitted <==

==> picture [562 x 101] intentionally omitted <==

==> picture [562 x 101] intentionally omitted <==

==> picture [562 x 102] intentionally omitted <==

----- Start of picture text ----- Immuron Files Amended Form F-1 and----- End of picture text -----

==> picture [562 x 101] intentionally omitted <==

----- Start of picture text ----- New Investor Presentation with the SEC----- End of picture text -----

ABN: 80 063 114 045

Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735

==> picture [563 x 98] intentionally omitted <==

Immuron Files Amended Form F-1 and New Investor Presentation with the SEC

Melbourne, Australia, 9 May 2017: Australian biopharmaceutical Company, Immuron Limited (ASX: IMC), announced today that it has filed the fourth amendment of its Form F-1 Registration Statement with the United States Securities and Exchange Commission (SEC). The amended F-1 can be viewed on the US Edgar filing platform.

Complementing this filing, the Company has also filed a new investor presentation which can also be viewed on the Edgar platform. Both documents will subsequently be lodged on the ASX platform following this announcement.

• • END - -

COMPANY CONTACT: IMMURON INVESTOR RELATIONS: Thomas Liquard Peter Taylor Chief Executive Officer NWR Communications Ph: +61 (0)3 9824 5254 Ph: +61 (0)4 1203 6231 thomasliquard@immuron.com peter@nwrcommunications.com.au

ABOUT IMMURON:

Immuron Ltd (ASX: IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhea whilst its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: http://www.immuron.com

FORWARD-LOOKING STATEMENTS:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forwardlooking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

ABN: 80 063 114 045

Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735